Precision medicine is starting to move from grand experiment—in which researchers use genomics to determine the molecular basis of diseases—to the clinical front lines, assisting physicians tailor their care decisions to individual individuals.
But if precision medicine is ever to recognize its promise of saving and enhancing numerous more lives, the health industry need to determine and right the fixable gaps among great science and clinical application. And it need to recognize those gaps that, for good scientific purpose, can not be fixed.
For starters, physicians need a lot more clinical analysis that establishes the clinical worth and enhanced wellness outcomes of precision medicine. No doctor is going to adjust his or her practice behavior without such robust proof. This is really distinct from the research-oriented method of focusing on establishing a strong genetic association amongst a genotype and a phenotype.
The sector also requirements to appear at the economic implications of introducing genetic testing into a patient’s ongoing clinical care “pathway,” not just as a indicates to produce a particular clinical outcome, but also to recognize the effect on the total cost of care.
Lack of reimbursement for such tests is stifling the improvement and adoption of precision medicine, and these sorts of research are a required step to alter that.
Acceptable proof thresholds
what it requires to convince a physician that a certain therapy works—also need to be defined. This is specifically difficult since the extent of evidence needed depends on the nature and use of the genetic test.